New registry aims to improve meningitis treatment for kids
NCT ID NCT07062445
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is creating a registry of 600 children under 18 with meningitis treated at hospitals across Brazil. Researchers will collect data during and after hospitalization to see how well current treatments work and what long-term problems, like hearing loss, occur. The goal is to use this real-world information to improve national care guidelines.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better national guidelines for treating childhood meningitis, potentially reducing deaths and long-term complications.
- What could go wrong
- This is an observational registry, not a treatment trial, so it won't directly test a new therapy. Results may vary across hospitals and may not apply to other countries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Pediatric population, \<17 years old, suspect of acute meningitis infection
- Ages
-
Up to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms\*: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR * Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR * Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions * In children younger than two years, in addition to the presentations listed above, consider fever with any of the following: irritability, persistent crying, somnolence, or bulging fontanelle. Exclusion Criteria: * Refusal to provide consent for study participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacterial infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Israelita Albert Einstein
RECRUITINGSão Paulo, São Paulo, 05653-000, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two blood tests may separate real kidney harm from a false alarm
- Can a computer model speed up sepsis blood tests?
- Can we predict who survives meningitis? a new study seeks answers
- Could a simple blood test curb antibiotic overuse in sick kids?
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can smarter antibiotic choices curb superbugs in liver disease?